Abstract
Several cellular and molecular processes participate in the pathologic changes of osteoarthritis (OA). However, the core molecular regulators of these processes are unclear, and no effective treatment for OA disease has been developed so far. ANGPTL2 is well known for its tissue remolding and pro-inflammation properties. However, the role of ANGPTL2 in osteoarthritis (OA) still remains unclear. To explore the expression level of ANGPTL2 in human OA cartilage and investigate the function of ANGPTL2 in human chondrocytes injury, qRT-PCR, western blot and immunohistochemistry were employed to investigate the expression of ANGPTL2 between human OA and normal cartilage samples. Next, human primary chondrocytes were treated with IL-1β to mimic OA progress in vitro, and the expression of ANGPTL2 were tested by qRT-PCR and western blot. Furthermore, the effect of ANGPTL2 in the expression of pro-inflammation cytokines (IL-1β, IL-6), proteolytic enzymes (MMP-1, MMP-13) and component of the cartilage matrix (COL2A1 and aggrecan) in human primary chondrocyte were explored by gain-of-function and loss-of-function methods. Finally, the nuclear factor kappa B (NF-κB) and p38/MAPK signaling pathways were also tested by western blot analysis. In this study, firstly, the expression level of ANGPTL2 was elevated both in human OA cartilage samples and IL-1β stimulated human chondrocytes. Secondly, ANGPTL2 upregulation promotes extracellular matrix (ECM) degradation and inflammation mediator production in human chondrocytes. Finally, ANGPTL2 activated the NF-κB and p38/MAPK signaling pathways via integrin α5β1. This study, for the first time, highlights that ANGPTL2 secreted by human chondrocytes plays a negative role in the pathogenesis of osteoarthritis, and it may be a potential therapeutic target in OA.
Similar content being viewed by others
Abbreviations
- ANGPTL2:
-
Angiopoietin-like 2
- NF-κB:
-
Nuclear factor kB
- MAPK:
-
Mitogen-activated protein kinase
- OA:
-
Osteoarthritis
- MMP:
-
Matrix metalloproteinase
- ECM:
-
Extracellular matrix
- IL:
-
Interleukin
- ITGA5:
-
Integrin α5
- ITGB1:
-
Integrin β1
References
Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, Sokolove J (2016) Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis (in eng). Nat Rev Rheumatol 12:580–592. https://doi.org/10.1038/nrrheum.2016.136
Loeser RF, Goldring SR, Scanzello CR, Goldring MB (2012) Osteoarthritis: a disease of the joint as an organ (in eng). Arthritis Rheum 64:1697–1707. https://doi.org/10.1002/art.34453
Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M, Lee YJ, Song YW, Herzog C, Theilmeier G, Pap T (2009) Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis (in eng). Nat Med 15:1072–1076. https://doi.org/10.1038/nm.1998
Karsenty G (2005) An aggrecanase and osteoarthritis (in eng). The New England journal of medicine 353:522–523. https://doi.org/10.1056/NEJMcibr051399
Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P, DeGennaro LJ (2001) Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice (in eng). J Clin Investig 107:35–44. https://doi.org/10.1172/jci10564
Zhang M, Mani SB, He Y, Hall AM, Xu L, Li Y, Zurakowski D, Jay GD, Warman ML (2016) Induced superficial chondrocyte death reduces catabolic cartilage damage in murine posttraumatic osteoarthritis (in eng). J Clin Investig 126:2893–2902. https://doi.org/10.1172/jci83676
Chen WP, Hu ZN, Jin LB, Wu LD (2017) Licochalcone A Inhibits MMPs and ADAMTSs via the NF-kappaB and Wnt/beta-Catenin Signaling Pathways in Rat Chondrocytes (in eng). Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 43:937–944. https://doi.org/10.1159/000481645
Yuan Y, Tan H, Dai P (2017) Kruppel-Like Factor 2 Regulates Degradation of Type II Collagen by Suppressing the Expression of Matrix Metalloproteinase (MMP)-13 (in eng). Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 42:2159–2168. https://doi.org/10.1159/000479991
Ma CH, Wu CH, Jou IM, Tu YK, Hung CH, Hsieh PL, Tsai KL (2018) PKR activation causes inflammation and MMP-13 secretion in human degenerated articular chondrocytes (in eng). Redox biology 14:72–81. https://doi.org/10.1016/j.redox.2017.08.011
Son YO, Park S, Kwak JS, Won Y, Choi WS, Rhee J, Chun CH, Ryu JH, Kim DK, Choi HS, Chun JS (2017) Estrogen-related receptor gamma causes osteoarthritis by upregulating extracellular matrix-degrading enzymes (in eng). Nature communications 8:2133. https://doi.org/10.1038/s41467-017-01868-8
Pelletier JP, Martel-Pelletier J, Abramson SB (2001) Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets (in eng). Arthritis Rheum 44:1237–1247. https://doi.org/10.1002/1529-0131(200106)44:6%3c1237:AID-ART214%3e3.0.CO;2-F
Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis (in eng). The New England journal of medicine 354:795–808. https://doi.org/10.1056/NEJMoa052771
Hunter DJ (2015) Viscosupplementation for Osteoarthritis of the Knee (in eng). The New England journal of medicine 372:2570. https://doi.org/10.1056/NEJMc1505801
Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI (1991) Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee (in eng). The New England journal of medicine 325:87–91. https://doi.org/10.1056/nejm199107113250203
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Juni P, Trelle S (2016) RETRACTED: effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis (in eng). Lancet (London, England) 387:2093–2105. https://doi.org/10.1016/s0140-6736(16)30002-2
Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT (2010) Tanezumab for the treatment of pain from osteoarthritis of the knee (in eng). The New England journal of medicine 363:1521–1531. https://doi.org/10.1056/NEJMoa0901510
Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P (2017) Celecoxib for osteoarthritis (in eng). The Cochrane database of systematic reviews 5:CD009865. https://doi.org/10.1002/14651858.CD009865.pub2
Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, Rasmussen S (2015) A Randomized, Controlled Trial of Total Knee Replacement (in eng). The New England journal of medicine 373:1597–1606. https://doi.org/10.1056/NEJMoa1505467
Loeser RF, Collins JA, Diekman BO (2016) Ageing and the pathogenesis of osteoarthritis (in eng). Nat Rev Rheumatol 12:412–420. https://doi.org/10.1038/nrrheum.2016.65
Kadomatsu T, Endo M, Miyata K, Oike Y (2014) Diverse roles of ANGPTL2 in physiology and pathophysiology (in eng). Trends in endocrinology and metabolism: TEM 25:245–254. https://doi.org/10.1016/j.tem.2014.03.012
Thorin-Trescases N, Thorin E (2014) Angiopoietin-like-2: a multifaceted protein with physiological and pathophysiological properties (in eng). Expert Rev Mol Med 16:e17. https://doi.org/10.1017/erm.2014.19
Aoi J, Endo M, Kadomatsu T, Miyata K, Nakano M, Horiguchi H, Ogata A, Odagiri H, Yano M, Araki K, Jinnin M, Ito T, Hirakawa S, Ihn H, Oike Y (2011) Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis (in eng). Can Res 71:7502–7512. https://doi.org/10.1158/0008-5472.can-11-1758
Odagiri H, Kadomatsu T, Endo M, Masuda T, Morioka MS, Fukuhara S, Miyamoto T, Kobayashi E, Miyata K, Aoi J, Horiguchi H, Nishimura N, Terada K, Yakushiji T, Manabe I, Mochizuki N, Mizuta H, Oike Y (2014) The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin alpha5beta1, p38 MAPK, and matrix metalloproteinases (in eng). Science Signaling 7:7. https://doi.org/10.1126/scisignal.2004612
Horio E, Kadomatsu T, Miyata K, Arai Y, Hosokawa K et al (2014) Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression (in eng). Arterioscler Thromb Vasc Biol 34:790–800. https://doi.org/10.1161/atvbaha.113.303116
Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y et al (2009) Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance (in eng). Cell Metab 10:178–188. https://doi.org/10.1016/j.cmet.2009.08.003
Corciulo C, Lendhey M, Wilder T, Schoen H, Cornelissen AS, Chang G, Kennedy OD, Cronstein BN (2017) Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression (in eng). Nature communications 8:15019. https://doi.org/10.1038/ncomms15019
Jacques C, Bereziat G, Humbert L, Olivier JL, Corvol MT, Masliah J, Berenbaum F (1997) Posttranscriptional effect of insulin-like growth factor-I on interleukin-1beta-induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes (in eng). J Clin Investig 99:1864–1872. https://doi.org/10.1172/jci119353
Meng F, Li Z, Zhang Z, Yang Z, Kang Y, Zhao X, Long D, Hu S, Gu M, He S, Wu P, Chang Z, He A, Liao W (2018) MicroRNA-193b-3p regulates chondrogenesis and chondrocyte metabolism by targeting HDAC3 (in eng). Theranostics 8:2862–2883. https://doi.org/10.7150/thno.23547
Hirasawa M, Takubo K, Osada H, Miyake S, Toda E, Endo M, Umezawa K, Tsubota K, Oike Y, Ozawa Y (2016) Angiopoietin-like Protein 2 Is a Multistep Regulator of Inflammatory Neovascularization in a Murine Model of Age-related Macular Degeneration (in eng). The Journal of biological chemistry 291:7373–7385. https://doi.org/10.1074/jbc.M115.710186
Tanoue H, Morinaga J, Yoshizawa T, Yugami M, Itoh H et al (2018) Angiopoietin-like protein 2 promotes chondrogenic differentiation during bone growth as a cartilage matrix factor (in eng). Osteoarthritis and cartilage 26:108–117. https://doi.org/10.1016/j.joca.2017.10.011
Bose S, Li B, He J, Lv H, Liu Y, Lv X, Zhang C, Zhu Y, Ai D (2019) c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow (in eng). Nature communications 129:1167–1179. https://doi.org/10.1038/s41467-019-09453-x10.1172/jci122440
Lee SJ, Lee CK, Kang S, Park I, Kim YH, Kim SK, Hong SP, Bae H, He Y, Kubota Y, Koh GY (2018) Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction (in eng). J Clin Investig 128:5018–5033. https://doi.org/10.1016/j.ccell.2018.11.01610.1172/jci99659
Duchet BJ, Hansel CS, Maynard SA, Chow LW, Stevens MM, Sundaram A, Chen C, Khalifeh-Soltani A, Atakilit A, Ren X, Qiu W, Jo H, DeGrado W, Huang X, Sheppard D (2017) Targeting integrin alpha5beta1 ameliorates severe airway hyperresponsiveness in experimental asthma (in eng). ACS Nano 127:365–374. https://doi.org/10.1021/acsnano.6b0597510.1172/jci88555
Goldring MB, Goldring SR (2010) Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis (in eng). Ann N Y Acad Sci 1192:230–237. https://doi.org/10.1111/j.1749-6632.2009.05240.x
Sellam J, Berenbaum F (2010) The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis (in eng). Nat Rev Rheumatol 6:625–635. https://doi.org/10.1038/nrrheum.2010.159
Karsdal MA, Bay-Jensen AC, Lories RJ, Abramson S, Spector T, Pastoureau P, Christiansen C, Attur M, Henriksen K, Goldring SR, Kraus V (2014) The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? (in eng). Ann Rheum Dis 73:336–348. https://doi.org/10.1136/annrheumdis-2013-204111
Liu-Bryan R, Terkeltaub R (2015) Emerging regulators of the inflammatory process in osteoarthritis (in eng). Nat Rev Rheumatol 11:35–44. https://doi.org/10.1038/nrrheum.2014.162
Felson DT (2006) Clinical practice. Osteoarthritis of the knee (in eng). The New England journal of medicine 354:841–848. https://doi.org/10.1056/NEJMcp051726
Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, Van Wart H, Poole AR (1997) Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage (in eng). J Clin Investig 99:1534–1545. https://doi.org/10.1172/jci119316
Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS (1997) Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints (in eng). J Clin Investig 100:93–106. https://doi.org/10.1172/jci119526
de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, Zuurmond AM, Schoones J, Toes RE, Huizinga TW, Kloppenburg M (2012) Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review (in eng). Osteoarthritis and cartilage 20:1484–1499. https://doi.org/10.1016/j.joca.2012.08.027
Chen LF, Greene WC (2004) Shaping the nuclear action of NF-kappaB (in eng). Nat Rev Mol Cell Biol 5:392–401. https://doi.org/10.1038/nrm1368
Kobayashi H, Chang SH, Mori D, Itoh S, Hirata M, Hosaka Y, Taniguchi Y, Okada K, Mori Y, Yano F, Chung UI, Akiyama H, Kawaguchi H, Tanaka S, Saito T (2016) Biphasic regulation of chondrocytes by Rela through induction of anti-apoptotic and catabolic target genes (in eng). Nature Communications 7:13336. https://doi.org/10.1038/ncomms13336
Kronenberg HM (2003) Developmental regulation of the growth plate (in eng). Nature 423:332–336. https://doi.org/10.1038/nature01657
van der Kraan PM, van den Berg WB (2012) Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? (in eng). Osteoarthritis and cartilage 20:223–232. https://doi.org/10.1016/j.joca.2011.12.003
Pesesse L, Sanchez C, Delcour JP, Bellahcene A, Baudouin C, Msika P, Henrotin Y (2013) Consequences of chondrocyte hypertrophy on osteoarthritic cartilage: potential effect on angiogenesis (in eng). Osteoarthritis and cartilage 21:1913–1923. https://doi.org/10.1016/j.joca.2013.08.018
Acknowledgements
We thank Kai Lin, Yinglei Fang, Penghui Ke for assistance in collecting cartilage samples.
Funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81672161) and National Undergraduate Traning Programs for Innovation and Entrepreneurship-China (No. 201810366025).
Author information
Authors and Affiliations
Contributions
Zongsheng Yin, Wei He and Jiegou Xu designed the study. Wenshan Shan, Zhenfei Ding, Guanjun Cui performed in vitro experiments. Chao Chen, Wei Huang, Wei Lu and Fuen Liu detected the expression level of ANGPTL2 in OA cartilage samples. Sha Luo participated in the supplementary experiment. Wenshan Shan wrote the paper.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval
All cartilage samples were obtained from the First Affiliated Hospital of Anhui Medical University. This research was approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University.
Informed consent
All patients obtained a written informed consent about the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
774_2019_1016_MOESM1_ESM.tif
Supplementary Fig. 1. Identification of human primary chondrocytes. SF1. A-C shows that type II collagen was high produced by human primary chondrocytes. Immunofluorescence of human primary chondrocytes with an anti-type II collagen antibody (SF1A). The nuclei of cells were revealed by the DAPI (SF1.B). Staining of human primary chondrocytes with toluidine blue, which reveals high production of proteoglycans in human chondrocytes (SF1.D). Scale bars (ABC) = 200 μm. Scale bars (D) = 100 μm (TIFF 77082 kb)
774_2019_1016_MOESM2_ESM.tif
Supplementary Fig. 2. Silencing of ANGPTL2 in chondrocyte. AB: Silencing of ANGPTL2 in vitro OA model Human chondrocytes were divided into four groups: Control, IL-1β (10 ng/mL), IL-1β (10 ng/ml) + siNC, IL-1β (10 ng/mL) + siANGPTL2. Chondrocytes were pretreated with siNC or siANGPTL2 for 24 h followed by stimulated with IL-1β (10 ng/ml) for 24 h, and then, RNA or protein was extracted from chondrocytes. (A) qRT-PCR and (B) Western Blot were used to evaluate the expression of ANGPTL2. CD: Silencing of ANGPTL2 in human primary chondrocyte without IL-1β. Human chondrocytes were divided into three groups: Control, siNC, siANGPTL2. Chondrocytes were pretreated with siNC or siANGPTL2 for 24 h and then, RNA or protein was extracted from chondrocytes. (A) Western Blot and (B) qRT-PCR were used to evaluate the expression of ANGPTL2. Results are expressed as mean ± SD. Welch Test followed by Games-Howell Test (Equal variances not assumed) (TIFF 9847 kb)
774_2019_1016_MOESM3_ESM.tif
Supplementary Fig. 3. Effects of ANGPTL2 on COL2A1 and aggrecan production in human primary chondrocytes. A-C Human chondrocytes were divided into four groups: Control, IL-1β (10 ng/mL), IL-1β (10 ng/ml) + siNC, IL-1β (10 ng/mL) + siANGPTL2. Chondrocytes were pretreated with siNC or siANGPTL2 for 24 h followed by stimulated with IL-1β (10 ng/ml) for 24 h, and then, RNA or protein was extracted from chondrocytes. (A)(B) qRT-PCR analysis for the mRNA expression levels of COL2A1 and aggrecan. (C)Western blots analysis for the protein expression of COL2A1 and aggrecan. D-F Human primary chondrocytes were treated with a serial dosage (0, 0.1, 0.2, 0.4 μg/ml) of rhANGPTL2 for 24 h. (D)(E) qRT-PCR analysis for the mRNA expression levels of COL2A1 and aggrecan. (F)Western blots analysis for the protein expression of COL2A1 and aggrecan. Results are expressed as mean ± SD. (D)Analysis of variance (ANOVA) followed by Bonferroni Test (equal variances). (A)Welch Test followed by Games-Howell Test (Equal variances not assumed). (BE) ANOVA Test (no significant) (TIFF 9789 kb)
774_2019_1016_MOESM4_ESM.tif
Supplementary Fig. 4. Effects of ANGPTL2 on caspase3 production in human primary chondrocytes. Human chondrocytes were divided into four groups: Control, IL-1β (10 ng/mL), IL-1β (10 ng/ml) + siNC, IL-1β (10 ng/mL) + siANGPTL2. Chondrocytes were pretreated with siNC or siANGPTL2 for 24 h followed by stimulated with IL-1β (10 ng/ml) for 24 h, and then, RNA or protein was extracted from chondrocytes. (A) Western Blot and (B) qRT-PCR were used to evaluate the expression of caspase3. Results are expressed as mean ± SD. ANOVA Test (no significant) (TIFF 4184 kb)
About this article
Cite this article
Shan, W., Cheng, C., Huang, W. et al. Angiopoietin-like 2 upregulation promotes human chondrocyte injury via NF-κB and p38/MAPK signaling pathway. J Bone Miner Metab 37, 976–986 (2019). https://doi.org/10.1007/s00774-019-01016-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-019-01016-w